The Impact of Adjuvant Chemotherapy Initiation Time on the Outcome of Cancer Breast

Mosalam, Nesreen Ahmed; Aziz, Heba Tharwat Abd El; Seed, Amr Shafik; Mohamed, Assma Wahid

doi:10.4172/2476-2261.1000113

J Oncol Transl Res

2017

DOI: 10.4172/2476-2261.1000113

|View full text |Cite

The Impact of Adjuvant Chemotherapy Initiation Time on the Outcome of Cancer Breast

Nesreen Ahmed Mosalam¹,

Heba Tharwat Abd El Aziz²,

Amr Shafik Seed³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Several studies have found that a delay in the initiation of chemotherapy may be associated with age, marital status, place of residence, tumor stage, and type of surgery, with the delay being greater in older patients, as well as in those living alone, from rural areas, with BC stage III, and having undergone surgeries with greater morbidity (mastectomy and ALND). 21,22 However, in our study, when analyzing the different variables that could influence the time to the initiation of chemotherapy, no statistically significant association was found for age, marital status, place of residence, number of comorbidities, tumor stage, type of surgery, or biological subtype (Table 3). We must take into account that these values were at the limit of…”

contrasting

confidence: 60%

Survival and Time to Initiation of Adjuvant Chemotherapy Among Breast Cancer Patients in Uruguay

Castillo¹,

Camejo²,

Rondan³

et al. 2021

BCTT

View full text Add to dashboard Cite

Introduction Increases in disease-free survival and overall survival (OS) with the use of adjuvant chemotherapy in early breast cancer (BC) are widely known; however, the optimal time to initiate treatment with adjuvant chemotherapy remains controversial. Objective To evaluate the time elapsed between surgery and the initiation of adjuvant chemotherapy and its possible impact on OS in patients diagnosed with BC stages I–III. Materials and Methods This retrospective study included 112 patients diagnosed with BC stages I–III who received adjuvant chemotherapy at the Mastology Unit of the Hospital de Clínicas in Uruguay from 2009 to 2019. OS was estimated using the Kaplan–Meier method, and a Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% confidence intervals. Results No statistically significant association was found between the time from surgery to the initiation of chemotherapy and the described variables. OS was worse for patients initiating chemotherapy more than 90 days after breast surgery (n = 19) (HR 7.63; p = 0.004) and between 61 and 90 days after surgery (n = 46) (HR 4.58; p = 0.040) compared to those who started before 30 days (n = 23). Controlling by type of surgery and stage, the prognosis of patients who started chemotherapy between 61 and 90 days after surgery was similar to that of patients who underwent chemotherapy within the first 30 days, controlling for surgery (HR 4.10; p = 0.056) and controlling for stage (HR 3.76; p = 0.075). Prognosis was worse for patients with stage III disease (p = 0.022) who underwent a mastectomy and/or axillary lymph node dissection (p = 0.025). Conclusion Patients who started chemotherapy more than 90 days following surgery and those with stage III disease or underwent mastectomy and/or axillary lymph node dissection who initiated it between 61 and 90 days had a worse OS. Multiple factors are involved in the time between surgery and the initiation of chemotherapy, and further studies are needed to evaluate which of these factors influence the delay of chemotherapy in order to design strategies to avoid such delays and their negative impact on survival.

show abstract

contrasting

confidence: 60%

Survival and Time to Initiation of Adjuvant Chemotherapy Among Breast Cancer Patients in Uruguay

Castillo¹,

Camejo²,

Rondan³

et al. 2021

BCTT

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Impact of Adjuvant Chemotherapy Initiation Time on the Outcome of Cancer Breast

Cited by 1 publication

References 16 publications

Survival and Time to Initiation of Adjuvant Chemotherapy Among Breast Cancer Patients in Uruguay

Survival and Time to Initiation of Adjuvant Chemotherapy Among Breast Cancer Patients in Uruguay

Contact Info

Product

Resources

About